Regulus Therapeutics (NASDAQ: RGLS) is one of 212 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Regulus Therapeutics to similar companies based on the strength of its valuation, risk, institutional ownership, dividends, earnings, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Regulus Therapeutics and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regulus Therapeutics 0 5 1 0 2.17
Regulus Therapeutics Competitors 490 2378 6455 122 2.66

Regulus Therapeutics currently has a consensus price target of $2.88, suggesting a potential upside of 163.76%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.68%. Given Regulus Therapeutics’ higher probable upside, research analysts clearly believe Regulus Therapeutics is more favorable than its peers.

Profitability

This table compares Regulus Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Regulus Therapeutics -31,460.47% -173.20% -90.45%
Regulus Therapeutics Competitors -3,960.65% -121.01% -43.99%

Insider & Institutional Ownership

22.3% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 4.8% of Regulus Therapeutics shares are held by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Regulus Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Regulus Therapeutics $1.19 million -$81.83 million -0.71
Regulus Therapeutics Competitors $220.75 million -$39.68 million -63.33

Regulus Therapeutics’ peers have higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Regulus Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Regulus Therapeutics’ peers have a beta of 1.54, meaning that their average stock price is 54% more volatile than the S&P 500.

Summary

Regulus Therapeutics peers beat Regulus Therapeutics on 10 of the 12 factors compared.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.